<DOC>
	<DOCNO>NCT01382069</DOCNO>
	<brief_summary>The long term objective develop new male hormone Dimethandrolone Undecanoate ( DMAU ) male hormonal contraceptive . The study two part . The first dose escalate study healthy ass safety tolerability single dose oral administration DMAUin healthy men . ( Completed ) The second study safety tolerability DMAU 28 day repeat daily dose DMAU healthy men . ( Currently Recruiting ) In part investigator also study pharmacokinetics Dimethandrolone ( DMA ) serum oral administration DMAU .</brief_summary>
	<brief_title>Phase 1 Study Dimethandrolone Undecanoate Healthy Men</brief_title>
	<detailed_description>The study conduct two center . 28-Day Repeat-Dose , Dose-Escalation Study : Based safety tolerability single dose study serum DMA level attain , three dos two formulation DMAU select dose-escalating 28-day repeat dose study . Safety assess subject receive low dosage additional men receive high dos 28 day . Up 100 men randomize receive either active drug identical number capsule placebo . The 24-hour detailed PK DMA assess day 1 28 . Trough level DMA obtain throughout 28-day period 48 72 hour last dose . In addition safety tolerability , suppression serum T , gonadotropin , SHBG also assess secondary pharmacodynamic ( PD ) endpoint . Psychosexual diary 7 consecutive day PHQ-9 ( questionnaire ) obtain end study period .</detailed_description>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>1 . Male volunteer good health confirm physical examination , medical history , clinical laboratory test blood urine time screen . 2 . 18 50 year age . 3 . BMI &lt; 33 calculated weight kg/ ( height m2 ) 4 . No history hormonal therapy use last three month prior first screen visit . 5 . Subject agree use recognize effective method contraception partner ( i.e . minimum , use doublebarrier contraception ) course study treatment recovery phase . 6 . Subjects refrain donate blood plasma study period . 7 . Subjects advise refrain/abstain alcoholic beverage grapefruit juice study period . 8 . Subjects use cannabis recreational drug least 4 week screen study . 9 . In opinion investigator , subject able comply protocol , understand sign inform consent HIPAA form . 10 . Does meet exclusion criterion . 1 . Men participate another clinical trial involve investigational drug within last 30 day prior first screen visit . 2 . Men live catchment 's area clinic within reasonable distance study site . 3 . Clinically significant abnormal physical laboratory finding screen . 4 . Elevated PSA ( level â‰¥ 2.5 ng/mL ) , accord local laboratory normal value . 5 . Abnormal serum chemistry value , accord local laboratory reference range indicate liver kidney dysfunction may consider clinically significant except : upper limit fast bilirubin le 2 mg/dL , upper limit cholesterol le 220 mg/dL , upper limit fast triglyceride le 200 mg/dL . 6 . Abnormal semen analyse abnormal semen concentration define WHO semen manual . 7 . Use androgens body build substance include nutritional supplement within 3 month first screen visit . 8 . Systolic BP &gt; 130 mm Hg Diastolic blood pressure BP &gt; 80 mm Hg ; ( ( BP ) Blood pressure take 3 time 5minute interval mean measurement consider ) . 9 . Clinically significant abnormal EKG QTc interval &gt; 450 msec . 10 . PHQ9 score 15 [ 28 day study ] . 11 . History hypertension , include hypertension control treatment . 12 . Known history primary testicular disease disorder hypothalamicpituitary axis . 13 . Benign malignant liver tumor ; active liver disease . 14 . History breast carcinoma . 15 . Known history androgen deficiency due hypothalamicpituitary testicular disease . 16 . Known history cardiac , renal , hepatic prostatic disease . 17 . Positive serology Hepatitis HIV screen visit . 18 . A serious systemic disease diabetes mellitus obesity ( body weight great BMI &gt; 33 kg/m2 ) . 19 . History know , untreated sleep apnea . 20 . Known suspected alcoholism drug abuse may affect metabolism/transformation steroid hormone study treatment compliance . 21 . Partner known pregnant . 22 . Men desire fertility within first 24 week study participation . 23 . Men participate competitive sport drug screening prohibit substance ( include anabolic steroid ) routine advise relative temporary hazard participate study may fertility sport status .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>androgen</keyword>
	<keyword>male contraception</keyword>
	<keyword>dimethandrolone</keyword>
	<keyword>healthy men</keyword>
</DOC>